IGC Pharma Announces Interim Results For IGC-AD1 In Reducing Alzheimer's Agitation; Study Achieved Primary End Point Demonstrating Clinical And Statistically Significant Reductions Compared To Placebo In Agitation Associated With Dementia Due To Alzheimer's Disease
IGC Pharma 公佈了 IGC-AD1 在減少阿爾茨海默氏症焦慮方面的中期業績;該研究達到了主要終點,表明與安慰劑相比,阿爾茨海默氏病引起的癡呆相關的焦慮在臨床和統計學上都有顯著的降低